Predictive Health Intelligence’s Post

What’s curious about this map? It shows the disparity between the hotspots of high disease prevalence for patients with decompensated liver disease and areas which have been historically research active. It is well documented that patients with #liverdisease are underserved. Developing new treatments that improve the outcome for this patient group remains an unmet area of clinical need. As an active CRO in #hepatology #clinicaltrials, we are delighted to collaborate with the UK hepatology community including Oliver Tavabie, Gautam Mehta, Rajiv Jalan, Daniel Green and the UK-Chronic Liver Failure network (UK-CLIF), on a review discussing the challenges and opportunities for innovating hepatology trials in the UK. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY ⇒ We propose a number of innovations in clinical trial design to improve access to clinical trials for patients, clinicians and investigators alike. ⇒ We highlight the importance of agreeing and implementing standards of care for this patient group, which should not just improve clinical outcomes but reduce heterogeneity in standard of care/placebo cohorts. ⇒ We discuss the potential role of collaboration with industry to improve the delivery of clinical trials. ⇒ We discuss the importance of ensuring the development of the next generation of investigators to ensure sustainability to this model of working. You can read the full review on the PHARMExcel website 👉 https://lnkd.in/dkg42TwU #Heptology #ClinicalTrials #Gastroenterology #LiverDisease #FrontlineGastroenterology #ClinicalResearch # Yvanne Enever

🧪 We are thrilled to announce that OWL Metabolomics has contributed to a groundbreaking study published in the United European Gastroenterology Journal! 🧬 In collaboration with Dr. Paula Iruzubieta, Dr. Javier Crespo, and researchers from 7 Spanish hospitals, our scientific team has made significant strides in the field of hepatology. The study, titled "One‐step non‐invasive diagnosis of metabolic dysfunction‐associated steatohepatitis (MASH) and fibrosis in high‐risk population," highlights the effectiveness of our OWLiver Panel, which includes the innovative MASEF Score. This blood-based test has demonstrated high accuracy and performance, offering a powerful tool for diagnosing MASH and liver fibrosis, particularly in high-risk populations. Discover more about this important research and its potential impact on liver disease diagnosis. 🔗Read the full study here: https://lnkd.in/dTCXmNTG #Hepatology #Metabolomics #LiverHealth #MedicalResearch #OWLMetabolomics #HealthcareInnovation

The recent change in nomenclature from non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD) has been paramount in differentiating individuals with hepatic steatosis based on cardiometabolic risk factors and alcohol consumption. This has led to the development of differentiating MASLD from metabolic dysfunction-associated alcoholic liver disease (MetALD) and pure ALD. But what about capturing patients at risk of developing metabolic dysfunction-associated steatohepatitis (MASH)? Our study delineates in the UKB cohort with MRI data that the prevalence of at-risk MASH is the lowest compared to other subtypes, but exhibited the highest risk of liver damage due to elevated aminotransferases, higher BMI and increased hepatic fat retention on imaging. This suggests that this patient population, though underrepresented, are crucial demographics to treat due to the risk of developing advanced-stage liver cancer and end-stage cirrhosis. https://lnkd.in/ewZH5XRK

🧪 We are thrilled to announce that Rubió Metabolomics has contributed to a groundbreaking study published in the United European Gastroenterology Journal! 🧬 In collaboration with Dr. Paula Iruzubieta, Dr. Javier Crespo, and researchers from 7 Spanish hospitals, our scientific team has made significant strides in the field of hepatology. The study, titled "One‐step non‐invasive diagnosis of metabolic dysfunction‐associated steatohepatitis (MASH) and fibrosis in high‐risk population," highlights the effectiveness of our OWLiver Panel, which includes the innovative MASEF Score. This blood-based test has demonstrated high accuracy and performance, offering a powerful tool for diagnosing MASH and liver fibrosis, particularly in high-risk populations. Discover more about this important research and its potential impact on liver disease diagnosis. 🔗Read the full study here: https://lnkd.in/dTCXmNTG #Hepatology #Metabolomics #LiverHealth #MedicalResearch #OWLMetabolomics #HealthcareInnovation

🌟 Exciting News! 🌟 I'm thrilled to share that our recent research on GLP-1 receptor agonists and their potential to lower the risk of acute pancreatitis recurrence has been highlighted in several media outlets! 🎉 Our study, presented at ENDO 2024, reveals that GLP-1 medications for type 2 diabetes and obesity may significantly reduce the risk of acute pancreatitis recurrence, offering new hope for effective disease management. This finding challenges previous concerns about the safety of these medications in patients with a history of pancreatitis. Check out the media coverage to learn more about our groundbreaking research: https://lnkd.in/gCtxq_vE https://lnkd.in/g3yKCuDj https://lnkd.in/g7jurPRd https://lnkd.in/gEXUg9wm https://lnkd.in/gAyUtHa9 I am grateful for the support from my colleagues at the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo and the incredible data resource from TriNetX. Our analysis covered 638,501 individuals, providing robust insights into the benefits of GLP-1 receptor agonists. This research underscores the importance of personalized medicine, where treatment decisions are tailored to the individual's specific health profile and needs. It also emphasizes the safety and potential of GLP-1 receptor agonists in managing acute pancreatitis recurrence in patients with obesity and type 2 diabetes. Thank you for your support, and let's continue to advance healthcare together! #ENDO2024 #DiabetesResearch #GLP1 #AcutePancreatitis #PersonalizedMedicine #HealthcareInnovation #UniversityAtBuffalo #TriNetX #Endocrine_News

#LNP #mRNATherapy #metabolicdisease | 𝗖𝗮𝗻 𝗺𝗥𝗡𝗔-𝗟𝗡𝗣 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 𝘂𝗻𝗹𝗼𝗰𝗸 𝗻𝗲𝘄 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 𝗳𝗼𝗿 𝗼𝗯𝗲𝘀𝗶𝘁𝘆, 𝗱𝗶𝗮𝗯𝗲𝘁𝗲𝘀, 𝗮𝗻𝗱 𝗹𝗶𝘃𝗲𝗿 𝗱𝗶𝘀𝗲𝗮𝘀𝗲𝘀 𝘂𝘀𝗶𝗻𝗴 𝗜𝗟-𝟮𝟮? Interleukin (IL)-22 is a promising therapeutic protein for obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease due to its hepatoprotective effects. However, its short serum half-life has limited clinical use. Enter mRNA-Lipid Nanoparticle (LNP) Technology! This innovative approach enables the body to produce IL-22 fusion protein, overcoming previous limitations. Researchers at #moderna Susanna Canali, Alexander W. Fischer, Mychael Nguyen, Karl Anderson, Lorna Wu, Anne-Renee Graham, and their team investigated the effects of mRNA-LNP encoding IL-22 on metabolic disease in various mouse models, showing significant potential for future treatments. Stay tuned for more on this groundbreaking research! For more check out here: https://lnkd.in/eetsDShz #MetabolicDisease #IL22 #Biotech #MedicalResearch #Innovation

Researchers from China developed a new nomogram that can predict the levels of nonceruloplasmin bound copper in the serum. According to the researchers, the nomogram could be useful in clinical practice and delay the progression of Wilson disease as well as improve clinical prognosis. The nomogram identified independent predictors for ideal serum levels of nonceruloplasmin bound copper in WD as being the age of the patient at diagnosis, the clinical classification of the disease, laminin, liver stiffness measurement, and copper to zinc ratio in 24-hour urinary excretions. Read more: https://brnw.ch/21wEBEr #RareDisease

The microbiota pattern in young-onset and old-onset #colorectal_cancer appears to be similar. NOTES: - well-known CRC-associated taxa, such as #Clostridium_symbiosum, #Peptostreptococcus_stomatis, #Parvimonas_micra and #Hungatella_hathewayi were significantly enriched in both old- and young-onset patients. - Similar strain-level patterns of #Fusobacterium_nucleatum, #Bacteroides_fragilis and #Escherichia_coli were observed for oCRC and yCRC. - Almost all old CRC-associated metagenomic pathways had directionally concordant changes in young patients.

One of the more challenging studies I have recently worked on, now out in Gastroenterology. Analyzing a rather complex and heterogeneous dataset (prospective study, both ulcerative colitis and Crohn's disease patients, three different biological therapies), we observed a-TNF to have a larger impact on the microbiota than the other biologicals studied. VDZ, here mostly prescribed as second-line treatment, appeared slightly less effective in patients hosting a Bact2-defined dysbiotic community. Developing a model for drug assignment, we unfortunately predict 53% of non-responders to be refractory also to both other therapies included in the study. Thanks to Duygu Koldere Vilain for the great graphical abstract. Temporary free access link: https://lnkd.in/eq4Pe7hJ. Bram Verstockt, Pedro Goncalves, João Sabino, Sara Vieira-Silva

Buntanetap, a small molecule being developed by Annovis Bio, Inc. for #neurodegenerative diseases, improved cognitive function in people with mild #Alzheimers positive for certain disease #biomarkers. Buntanetap, formerly known as ANVS401 or Posiphen, is in clinical testing for Alzheimer’s and #ParkinsonsDisease. Annovis will request for an end-of-Phase 2 meeting with the FDA to discuss next steps. A longer, Phase 3 study with enough patients with early Alzheimer’s is planned to study buntanetap’s potential to modify the course of disease. All three doses of buntanetap resulted in a reduction in the levels of total tau protein, supporting buntanetap’s mechanism of action and suggesting disease-modifying benefits. #alzheimersdisease